* Alkermes Inc., of Cambridge, Mass., received patent No. 5,506,206covering the chemical composition of the company's receptor-mediated permeabilizer-7, which is an agent for drug delivery to thebrain.
* American Biogenetic Sciences Inc., of Copiague, N.Y., receivedpatent No. 5,492,812, titled "diagnostic method for Alzheimer'sdisease by screening for tau peptides in the blood of a patient." Thepatent covers the company's tau-peptide screening test, which detectstau-peptide fragments released in the blood by degenerating neurons.
* Aradigm Corp., of Hayward, Calif., received two patents. No.5,497,763, titled "disposable package for intrapulmonary delivery ofaerosolized formulations," covers a single-dose packet used in thecompany's AERx pulmonary delivery system for aerosols made fromliquid drugs. Patent No. 5,497,764, titled "medication cassette for anautomatic aerosol medication delivery system," covers a disposabledrug cassette for use with the company's SmartMist asthmamanagement system.
* Aronex Pharmaceuticals Inc., of The Woodlands, Texas, received apatent covering use of its integrase inhibitor, AR177, and itsanalogues to inhibit HIV. Integrase is an enzyme that enables HIV tointegrate with the human genome.
* Athena Neurosciences Inc., of South San Francisco, received patentNo. 5,508,167 covering use of apolipoprotein E (ApoE) for diagnosisof Alzheimer's disease. ApoE is expressed in three different geneforms _ ApoE2, ApoE3 and ApoE4. People who inherit ApoE4 haveincreased probability that their dementia is caused by Alzheimer's.
* Cambridge Neuroscience Inc., of Cambridge, Mass., received apatent covering composition of matter for glial growth factor 2,which is a member of the neuregulin family of proteins produced bycells of the nervous system. Neuregulins are believed to play a role indevelopment of the nervous system and regeneration of neural andmuscular systems.
* Dekalb Genetics Corp., of Dekalb, Ill., received patent No.5,492,547 covering prediction of corn yield using inherited geneticmarkers.
* GelTex Pharmaceuticals Inc., of Waltham, Mass., received twopatents. No. 5,487,888 covers technology for non-absorbed, polymer-based pharmaceuticals that bind to iron in the gastrointestinal tractand No. 5,496,545 covers RenaGel phosphate binder, a non-absorbed, polymer-based drug for patients with end-stage kidneydisease.
* Geron Corp., of Menlo Park, Calif., received a patent coveringdetection of telomerase for diagnosing cancer. The patent is co-owned by the University of Texas Southwestern Medical Center inDallas. Telomerase is an immortalizing enzyme found in high levelsin all cancer cells, but is inactive in nearly all normal cells.
* Idec Pharmaceuticals Corp., of San Diego, received a patentproviding protection for its Primatized antibodies, which combinecomponents of macaque monkey and human antibodies.
* Immune Response Corp., of Carlsbad, Calif., received a patent,titled "methods of identifying lymphocytes with mutator phenotypes."The technology, co-owned by the University of Vermont, identifiescells in the blood with increased genetic mutations.
* Interferon Sciences Inc., of New Brunswick, N.J., received patentNo. 5,503,828, titled "improved alpha interferon composition andmethod for its production from human peripheral blood leukocytes."The patent protects the manufacture, use and sale of the company'snatural alpha interferon.
* Isis Pharmaceuticals Inc., of Carlsbad, Calif., received patent No.5,489,677 covering composition of matter for a family of antisensebackbone modifications with methylene methyl imino and relatedchemical constructs to replace the phosphodiester orphosphorothioate backbone of antisense compounds.
* Lidak Pharmaceuticals Inc., of La Jolla, Calif., received a patentbroadening protection for Lidakol, the company's n-docosanol 10percent cream, and covering it for topical treatment of viral andinflammatory diseases and associated pain.
* LXR Biotechnology Inc., of Richmond, Calif., received a patent formaspin, a tumor suppressor protein found in breast tissue.
* Procept Inc., of Cambridge, Mass., received a patent coveringcomposition of matter for a class of low molecular weightcompounds that inhibit CD4+ T cell proliferation. The compoundsare components of the company's PIC 060 analogue program, whichtargets organ transplant rejection, rheumatoid arthritis, insulin-dependent diabetes and psoriasis.
* Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., received apatent covering the gene encoding the Tie-2 ligand protein andmethod of using the gene to make the protein. The Tie-2 ligand mayhave a role in angiogenesis and hematopoiesis. The ligand binds tothe Tie-2 receptor, which is expressed in vascular endothelial cells.
* Somatix Therapy Corp., of Alameda, Calif., received three patentsrelated to gene therapy. The first covers genetic modification of livercells to treat diseases and is co-owned by the Whitehead Institute forBiomedical Research at the Massachusetts Institute of Technology, inCambridge, Mass. The second patent covers a method of implantingin vivo retroviral producer cells for gene transfer near cancer cellsand is co-owned by the University of California at San Diego. Thethird patent, co-owned by the Whitehead Institute, covers thecompany's GVAX cancer vaccine for increasing immune systemresponse using tumor cells expressing granulocyte-macrophagecolony stimulating factor.
* Targeted Genetics Corp., of Seattle, received patent No. 5,470,726,covering a retrovirus packaging cell line, called PG13, which is usedto produce retroviral vectors for gene transfer. The patent is co-owned by the Fred Hutchinson Cancer Research Center, in Seattle.
* VivoRx Inc., of Santa Monica, Calif., received a patent coveringcomposition and method for encapsulating biologically activematerials, such as cells, in natural and synthetic polymers.
* Xoma Corp., of Berkeley, Calif., received two patents related tomanufacturing capability and basic research for itsbactericidal/permeability-increasing protein (BPI). Patent No.5,488,034 covers pharmaceutical forms of BPI for storage andshipping and patent No. 5,489,676, covers polypeptides that mayboost BPI's ability to kill gram-negative bacteria.
(c) 1997 American Health Consultants. All rights reserved.